Clinical Trial

Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to investigate the preventive effects of electroacupuncture on immune-related adverse events (irAEs) in patients with malignant solid tumors at the neoadjuvant stage, locally advanced, unresectable, or metastatic stages, who are receiving immune checkpoint inhibitors (ICIs) monotherapy, ICIs combined with anti-angiogenic agents, or ICIs combined with chemotherapy. The study will evaluate the efficacy, safety and mechanisms of electroacupuncture in preventing irAEs in a multicenter setting.
Trial Details
NCT Number NCT06891521
Lead Sponsor Qinghai Red Cross Hospital
Conditions Cancer, Adverse Events
Enrollment 123 participants
Start Date 2025-03-20
Primary Completion 2027-03-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-24